October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
4 citations
,
September 2024 in “BMC Cancer” July 2010 in “PharmacoEconomics & Outcomes News”
January 2007 in “Acta Veterinaria Brno” Trilostane treatment successfully restored hair growth in a dog with alopecia X.
August 2020 in “SKIN The Journal of Cutaneous Medicine” Cetuximab can cause skin cysts after acne-like eruptions.
8 citations
,
January 1998 in “PubMed” 125 citations
,
May 2010 in “Pediatric dermatology” Systemic treatment is necessary for tinea capitis in children, with griseofulvin preferred for Microsporum infections.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
2 citations
,
June 2025 in “Drug Testing and Analysis” The method effectively detects MeT and TP in dried blood spots after cream application.
August 2021 in “Skin appendage disorders” Two people lost hair unexpectedly after getting a common hair loss treatment with a drug called Dutasteride.
7 citations
,
April 2006 in “Experimental Neurology” Finasteride blocks deoxycorticosterone's anticonvulsant effects in infant rats, but indomethacin doesn't.
3 citations
,
January 2025 in “International Journal of Biological Macromolecules” A new microneedle patch effectively promotes hair regrowth with less frequent dosing.
3 citations
,
September 1973 in “Archives of dermatology” Applying a tretinoin cream can remove hair plugs and treat trichostasis spinulosa.
31 citations
,
January 1989 in “The Prostate/The prostate” Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.
February 2017 in “Cancer Research” Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
Certain antiparasitics and antidepressants show promise for treating cryptococcosis, especially when combined with fluconazole.
6 citations
,
May 2022 in “Research and reports in urology” Caesalpinia bonduc seed extracts may help treat enlarged prostate in rats.
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
August 2025 in “International Journal of Biochemistry Research & Review” Glyphaea brevis and Monodora myristica can protect against finasteride's harmful effects on blood and oxidative stress in male rats.
46 citations
,
April 1982 in “Journal of the American Academy of Dermatology” Isotretinoin shrinks sebaceous glands without affecting hair or skin color, unlike etretinate.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology”
June 2018 in “Reactions Weekly” A 65-year-old man developed a serious skin cancer linked to a drug he was taking for a fungal infection after a bone marrow transplant.
34 citations
,
May 1987 in “European Journal of Pediatrics” Buserelin safely and effectively suppresses early puberty, potentially improving final height.
May 2025 in “International Journal of Trichology” Topical tofacitinib may help regrow hair in children with alopecia totalis.
4 citations
,
July 2019 in “Journal of cosmetic dermatology” Both 0.01% and 0.03% bimatoprost safely improve eyebrow fullness, with a patient preference for the 0.03% concentration.
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.